



CPAL

Central Pennsylvania Alliance Laboratory

Technical Bulletin

No. 86

December 2, 2010

KRAS Mutation Assay Change

Contact:

Dr. Jeffrey Wisotzkey, 717-851-1422
Technical Director, CPAL

Jill Johns, MT(ASCP), SH, QCYM, 717-851-4320
Operations Manager, CPAL

Effective Date: 12/06/2010

Summary: Effective immediately the KRAS Mutational Assay will interrogate codons 12 and 13. Codon 61 will no longer be included in the assay. Codon 61 mutations are rare and the current clinical utility for codon 61 mutational analyses is not well characterized. Should further clinical data become available in support of the analysis of this codon region of the KRAS gene, CPAL will consider re-instituting this portion of the assay.

Specific questions or concerns may be addressed to Dr. Wisotzkey